Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein may hold key to depression treatment success

NCT ID NCT02051413

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether certain proteins called beta-arrestins can predict how well people with major depression respond to the antidepressant venlafaxine (Effexor). Researchers followed 67 patients for three months, measuring their depression symptoms and checking blood samples for these proteins. The goal was to find a simple biological marker that could help doctors choose the right treatment from the start.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
venlafaxine (extended release)
What this could lead to
If successful, this could help doctors predict which patients will benefit from venlafaxine, making depression treatment more personalized.
What could go wrong
This is a small, early-stage study (67 participants) looking at biological markers, not a treatment itself. The findings may not lead to a practical test or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

67 people

The number who actually took part.

Started

Feb 2014

Finished

May 2018

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major Depressive Disorder * current Major Depressive Episode * Hamilton Depression Rating Scale score \> 18 * requiring a new treatment with venlafaxine * written informed consent Exclusion Criteria: * bipolar disorder * psychotic disorder * unstable somatic condition * contraindication to cerebral RMI * current treatment with mood stabilizers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder Major depressive episode

Contacts and locations

Locations

  • CHU de Bicetre

    Le Kremlin-Bicêtre, 94275, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.